Navigation Links
Newport Board Group, a National Business Advisory Firm of CEOs Cautions Buyers on 5 Questions to Ask Before Acquiring a Technology-Based Middle Market Company
Date:6/19/2013

San Francisco, CA (PRWEB) June 19, 2013

Middle market merger and acquisition (M&A) activity has been accelerating throughout 2013 across all industries as cash rich buyers seek to place their capital in productive assets. Despite the differences across industries, all M&A transactions have a good deal in common. The acquirer must perform rigorous due diligence to verify the history and quality of the target company’s earnings. Potential risks must be carefully considered.

But when due diligence involves a middle market company, whose value consists largely of its technology and intellectual property (IP), one issue is especially important. The acquirer or merger partner must question the future value and relevance of the acquired company’s technology.

Consider what is at stake in many acquisitions. To satisfy their investors and drive a rising valuation, firms that own a portfolio of niche technology manufacturing companies must deliver top and bottom line growth every quarter. To meet this goal, the parent company or private equity sponsor needs to see consistent organic growth and margin improvement from operational efficiencies.

Avoiding an M&A Train Wreck

Too often the evaluation of a company and its products rests on a forecast of future growth that projects past revenue trends forward. A buyer or merger partner must be prepared to ask some tough questions about whether its core technology will continue to deliver value. If its core technology is in transition or is likely to be soon, the impact on the company’s future product road map must be carefully considered.

5 Questions to Ask

To validate your investment hypothesis, a buyer should ask five key questions:
1. Do the CEO and management responsible for R&D and Marketing have a well-grounded conviction about where their technology and products are headed?
2. Does the technology deployed in the product have a future life--or is it about to be replaced or significantly modified?
3. Does the company have a history of predicting market, product and technology transitions accurately—and developing a road map to plan product transitions?
4. Has the company demonstrated the engineering, R&D and marketing capabilities to manage such product transitions?
5. Does the company have a record achieving revenue growth from new products?

A Real Life Example

A niche technology manufacturing company in the electronics industry was acquired by a larger firm. Due diligence did not uncover any issues regarding threats from new technology to its core, cash-producing products. Shortly after the company was bought, two issues arose, threatening the future of the business, neither of which was uncovered in due diligence.
Issue 1 – The core electronics/intellectual property supplied by outside vendor partners was becoming obsolete and not available for future product designs.
Issue 2 – Competitors were making advances in the area of the company’s core electronics technology, lowering barriers to entry and producing new entrants whose lower cost alternatives threatened the company’s leadership position. The experience of the R&D personnel of the acquired company was with the older technology. The company was thrown into turnaround mode. Its response was:
1. Cost cutting – because expected revenues and growth were delayed.
2. Launching an aggressive search for an outside development team to deliver a “crash” project to develop electronics compatible with the new technology.
3. Asking customers to wait and not place orders with competitors until the new products were ready.

M&A Failed to Deliver

With great difficulty, the company accomplished a near-term turnaround. Internal personnel were replaced with outsourced talent, a painful experience for all. Many customers waited to buy the new products and were pleased with them. The short term crisis was averted. But over the longer term the financial justification for making the acquisition failed to materialize. The company was eventually sold.

Learning the Right Lessons

All could have been avoided if the proper analysis and evaluation had been done before the deal was consummated. The lessons of experience were:

  • Especially where an acquisition strategy creates pressure to deliver quarterly results, proper due diligence is critical to evaluate the likely future financial gain from a given technology.
  • The analysis must address the availability of complementary and competitive IP elsewhere in the company’s ecosystem.
  • The buyer must have the right R&D talent and know how in-house to identify and license external IP to develop next generation products.
  • Firms should complement their internal engineering and product development talent with out-sourced experience. This is especially true of smaller companies that have limited development budgets.

Now is a great time to buy or merge with middle market companies whose products incorporate fast changing technology. But rigorous due diligence as to the future of the technology they are acquiring is required if the buyer is to have a chance to achieve the results they seek.

Michael Gioseffi is a partner in the Southern California practice of Newport Board Group. Mike can be reached at (626)253-4799.

Read the full story at http://www.prweb.com/releases/2013/6/prweb10841883.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Newport Board Group, a National Business Advisory Firm of CEOs That Serves the Middle Market, Issues Guidance for Companies Considering a Sale in 2013
2. Newport Beach Facelift Specialist's Tips on Skin Care Before and After Surgery
3. Newport Beach Cosmetic Dentist John Ravera Adds New Member to Dental Team
4. Newport Board Group, a National Business Advisory Firm of CEOs Serving the Emerging Middle Market, Releases a Technology Roadmap for Private Companies
5. Private Companies Will Face Increased Competition for Sales in 2013 - Newport Board Group Releases Seven Strategies Designed to Improve Customer Retention
6. d'Oliveira & Associates Helps Newport Woman Receive $150,000 Settlement for Auto Accident; Case: MI-11889
7. Radiology Business Management Association Announces Board of Directors and Officers for 2013-2014
8. Controversial Detox Center Billboard Appearing in South Florida
9. The Women’s Board of Wolfson Children’s Hospital Announces 2013-2014 Florida Forum Lineup
10. Ascendant Diagnostics™ Welcomes Three to Board of Directors
11. Board Certified San Diego Dermatologist Sabrina G. Fabi, MD, Gives Ultherapy® Workshop in Bangkok, Singapore & Seoul
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... Healthcare Associates of ... Center at Craig Ranch building at 8080 State Highway 121, Suite 210, McKinney, Texas ... easy access to Highway 121. , As the practice has grown, the need for ...
(Date:2/24/2017)... , ... February 24, 2017 , ... The International Association ... annual “Imagine Me Beyond What You See” body image mannequin art competition. Selected from ... be showcased and the winner revealed at the 31st annual iaedp Symposium, March 22 ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... again hosted their Military Wedding Giveaway, with the winning couple announced on Feb. ... with services generously donated from local vendors: A Matter of Taste, Ryan Rousseau ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... outlet with a clinician-based audience, will be participating in Rare Disease Day events, ... Washington, D.C. In addition, Rare Disease Report, a website, weekly e-newsletter and quarterly ...
(Date:2/23/2017)... IPSWICH, Mass. (PRWEB) , ... February 23, 2017 ... ... chosen as an approved content provider for the National Institute for Health ... care and social care-related organizations in the National Health Service (NHS) to search, ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., an ... that it has acquired exclusive worldwide rights to ... innovative HDAC inhibitor targeting hematological and solid tumors. ... Phase 1 and 2 clinical trials of Abexinostat ... have already been completed, demonstrating that Abexinostat ...
(Date:2/23/2017)... Feb. 23, 2017  Genesis Healthcare Services has merged ... was made by Bill Monast , President and ... and Nathan Feltman , executives with Home Health ... LLC. This acquisition helps Hospice Cloud ... technology enabled durable medical equipment (DME) solutions for the ...
(Date:2/23/2017)... REDWOOD CITY, Calif., Feb. 23, 2017 Nevro Corp. ... innovative evidence-based solutions for the treatment of chronic pain, today ... ended December 31, 2016. 2016 Accomplishment & ... the full year 2016, an increase of 228% as reported, ... million for 2016, an increase of 612% over the prior ...
Breaking Medicine Technology: